Is BioNTech Stock a No-Brainer Buy on the Dip?
2026-09-02 19:10
•Prosper Junior Bakiny •The Motley Fool
••• •••••• Axe Cap view
BioNTech’s Cancer Bet: Worth Watching, Not Chasing
BioNTech’s mRNA cancer pipeline shines, but valuation and risks argue for caution on the JSE.
BioNTech’s steep share price drop—about 70% over the last five years—reflects the fading of its initial COVID vaccine windfall. But the recent success of Moderna and Merck's personalized cancer vaccine trial reignites interest in mRNA’s broader potential. This matters locally because the biotech innovation cycle hints at long-term growth beyond pandemics—something South African investors often overlook in health tech narratives. Yet, BioNTech, valued at $25.4 billion, still isn’t profitable and faces hefty clinical risks. The upcoming trial results from its oncology candidates like BNT113 and pumitamig will be critical. If these fail, the share could sink further. While the rand-dollar rate (USD/ZAR) remains volatile, adding global biotech exposure via ETFs or big pharma partnerships might be a pragmatic starting point from here. Don’t mistake hype for a no-brainer buy just yet—patience will matter more than urgency with these stocks. this is just our opinion and not financial advice
Watch BioNTech closely but avoid buying aggressively until clinical data improve and valuation becomes more attractive. Consider selective exposure through diversified biotech or pharma names for a balanced risk reward.
- BNTX
- USD/ZAR
- Clinical trial failures
- Prolonged vaccine demand decline
- Rand volatility affecting offshore returns
6/10
BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.
Our take is based on reporting first published by The Motley Fool.